Hollenbeck Diagnostic
New Product for Diagnosis of Growth Hormone Deficiency (GHD)
Hollenbeck Pharmaceuticals plans to bring a new Growth Hormone Deficiency (GHD) diagnostic for adults and children to the market. The FDA has granted it orphan drug designation which provides us with incentives, including market exclusivity.
Supported by extensive research on the diagnostic, previous FDA approval, and interest from clinicians, this is a high confidence project with modest start-up costs and a short time to revenue.